GLUCAGON-LIKE peptide 1 receptor agonist use significantly lowers the long-term risk of total knee arthroplasty in osteoarthritis. In a large multicenter cohort study analyzing over 42,000 propensity score-matched adults with knee osteoarthritis, GLP-1 receptor agonists demonstrated significant, duration-dependent reductions in surgical progression. These findings suggest that targeting metabolic pathways may provide meaningful joint preservation strategies for patients with concurrent obesity or metabolic disorders.
Researchers evaluated clinical records from the TriNetX Global Research Network between 2010 and 2024, stratifying patients by treatment duration and drug class. Patients receiving any GLP-1 receptor agonist for one year exhibited a significant reduction in total knee arthroplasty incidence compared to non-exposed controls, achieving an absolute risk difference of -2.80 percentage points at eight years (hazard ratio 0.90, 95% CI 0.83–0.98, p < 0.001).
Longer therapy yielded even greater joint protection. Patients maintained on GLP-1 receptor agonists for three years achieved an absolute risk difference of -3.25 percentage points at eight years (hazard ratio 0.85, 95% CI 0.80–0.90).
The risk reduction was most pronounced among patients receiving new-generation agents, specifically semaglutide or tirzepatide. For individuals prescribed three years of new-generation GLP-1 therapy, the cumulative incidence of knee arthroplasty dropped by 4.71 percentage points at eight years (hazard ratio 0.72, 95% CI 0.67–0.78).
End-stage knee osteoarthritis traditionally offers few disease-modifying pharmacotherapies, leaving total knee replacement as the primary definitive intervention. However, obesity-related osteoarthritis is increasingly recognized as a metabolically active disease involving systemic inflammation and joint tissue catabolism. While previous trials confirmed that semaglutide reduces body weight and musculoskeletal pain, the current observational data indicate that sustained incretin therapy may attenuate structural joint destruction or delay surgical thresholds.
From a public health standpoint, a 1.44 percentage point reduction in one-year arthroplasty incidence after three years of new-generation therapy could avert approximately 14,400 surgeries annually across the United States. While prospective randomized trials are needed to confirm causality, GLP-1 receptor agonists present a viable non-surgical strategy to preserve joint health in high-risk metabolic phenotypes.
Reference
Carter V et al. Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Reg Anesth Pain Med. 2026;doi:10.1136/rapm-2026-107658.
Featured Image: anut21ng Stock on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
